Although riociguat is the only approved therapy for inoperable and persistent/recurrent CTEPH, off-label treatment with drugs approved for PAH, including PDE5 inhibitors, ERAs, and prostanoids, is common [9, 16–18]. This evidence concerns the gene PDE5A and chronic thromboembolic pulmonary hypertension.